Research programme: thyroid hormone receptor beta agonists - Karo Pharma

Drug Profile

Research programme: thyroid hormone receptor beta agonists - Karo Pharma

Alternative Names: KB-141

Latest Information Update: 21 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Karo Bio
  • Class Phenyl ethers; Phenylacetates
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 06 May 2004 Bristol-Myers Squibb announced its decision to return rights to the lead compound to Karo Bio and discontinued internal development on this programme
  • 06 May 2004 Preclinical trials in Obesity in Sweden (unspecified route)
  • 23 Sep 2003 A preclinical study has been added to the Obesity pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top